Table 1 Patient characteristics
From: Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm3)
| Age (yrs) | Percent patients (n = 57) | |
|---|---|---|
| <60 | 7 | |
| 60-69 | 45.6 | |
| 70-79 | 35.1 | |
| ≥80 | 12.3 | |
| Race | ||
| White | 54.4 | |
| Black | 40.4 | |
| Other | 5.3 | |
| Pre-treatment PSA (ng/ml) | ||
| ≤10 | 77.2 | |
| 10 < PSA ≤ 20 | 15.8 | |
| >20 | 7 | |
| T-Stage | ||
| T1c | 73.7 | |
| T2a | 12.3 | |
| T2b | 12.3 | |
| T2c | 1.8 | |
| Gleason score | ||
| 5 | 1.8 | |
| 6 | 44 | |
| 7 | 42 | |
| 8 | 10.4 | |
| Other | 1.8 | |
| Risk group | ||
| Low risk | 40.4 | |
| Intermediate risk | 43.9 | |
| High risk | 15.7 | |
| Hormone treatment | ||
| Yes | 33 | |
| No | 67 | |
| Dose | ||
| 35 Gy | 19.3 | |
| 35.25 Gy | 1.8 | |
| 36.25 Gy | 78.9 | |
| α 1A Inhibitor (Flomax) | ||
| Yes | 37 | |
| No | 63 | |